StemCell Therapy

Barron's

iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research report report published on Wednesday, April 5th. They currently have $298.93 target ... iShares NASDAQ Biotechnology Index (IBB) Stake Increased by ...Markets Daily iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc.Transcript Daily iShares NASDAQ Biotechnology Index (IBB) Stock Rating Upgraded ...Sports Perspectives Barron's -Petro Global News 24 -Chaffey Breeze all 14 news articles »

View post:
iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. - The Cerbat Gem

Dr. Felister Makini, Deputy Director General (crops) at the Kenya Agricultural & Livestock Research Organization (KALRO), noted that African women play a critical role in ensuring food security. She urged the government to make farming easier for them by providing modern tools such as biotechnology. As African women, we are the ones who suffer most whenever drought and food shortages strike, despite the availability of technological solutions to these problems, she said. We need to speak with one voice and advocate for a predictable policy environment. I have children and a family to protect. I cannot advocate for something that I know would affect them she added.

On her part, Prof. Caroline Thoruwa, Chairperson, African Women in Science and Engineering (AWSE), noted that for Africa to advance in agri-biotech, women must be involved. It is time to tell the public about the positive side of biotechnology. We need to raise up the status of women in biotechnology and also encourage women to network in order to achieve the noble goal of sharing their science, she said.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:AFRICAN WOMEN IN BIOSCIENCES CALL FOR SUPPORTIVE POLICIES ON BIOTECHNOLOGY

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Read the rest here:
Kenyan scientists push for female farmers' access to biotechnology - Genetic Literacy Project

The Cerbat Gem

Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. - American Depositary Shares (APOP) The Cerbat Gem Rodman & Renshaw reissued their buy rating on shares of Cellect Biotechnology Ltd. American Depositary Shares (NASDAQ:APOP) in a research report report published on Tuesday, April 4th. Rodman & Renshaw currently has a $1.00 price objective on ... Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.Nasdaq all 2 news articles »

Read the original post:
Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. - American Depositary Shares (APOP) - The Cerbat Gem

Cellect Biotechnology Ltd, based in Israel, has developed an innovative technology which enables the production of stem cells to therapies and treatments that require stem cells as the main raw material. The company trades on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, and had a market capitalisation at TASE of ca. 45 million USD (prior to the release of Frost & Sullivan report today).

Frost & Sullivan publishes equity research reports on technology, biomed and healthcare companies that are listed on the TASE, within the framework of the analysis program that the TASE has initiated. Key goals of the program are enhancing global awareness of these companies and enabling more informed investment decisions by investors interested in hot Israeli hi-tech and healthcare companies.

In the coming months, Frost & Sullivan will release 9 additional initiation coverage reports, covering the other companies that have joined the programme: 6 biomed companies Aposense, Brainsway, BiolineRX, Kitov Pharmaceuticals, D.N.A. Biomedical Solutions, and Redhill Biopharma; and 3 technology companies: Safe-T Group, Vonetize and Energix Renewable Energies.

For the purpose of equity research services, Frost & Sullivan, the leading global consulting, and market research firm, will leverage relevant analysts, experts and growth consultiants among a staff of 1,800, at ca. 50 branches across 6 continents, including in Israel. Frost & Sullivan will utilize the experience and know-how accumulated over the course of 55 years in medical technologies, life sciences, technology, energy, and other industrial fields, including the publication of tens of thousands of market and technology research reports, and economic analyses and valuations.

Starting September 2016 Edison Investment Research released analyses of 11 companies, and a significant increase in trading volume and in the exposure of the companies included in the project to both the local and foreign investing public is evident. It is noteworthy that in most of the reviewed dual listings, trading volume has increased significantly both in Israel and the United States.

See the rest here:
Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology - Equity Research Is Published In The ... - Exchange News Direct

Rheumatoid arthritis is a long-term condition that causes pain, swelling and stiffness in the joints and mainly affects the hands feet and wrists.

People suffering with rheumatoid arthritis often experience periods where the symptoms are worse.

These can be difficult to predict but there is treatment available which can ease pain and prevent long-term damage to the joints.

Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss.

New research led by Sarah Skeoch and Professor Ian Bruce at the Arthritis Research UK Centre for Epidemiology at the University of Manchester, looked at the link between chronic inflammation and increased cardiovascular risk.

GETTY

The research used advanced imaging techniques to highlight the greater risk of cardiovascular problems among people with rheumatoid arthritis.

Published in the medical journal Scientific Reports, the researchers aimed to provide evidence that chronic inflammation drives increased cardiovascular risk in patients by accelerating atherosclerosis.

Atherosclerosis is a condition characterised by the buildup of fatty substances called plaques in the arteries - while also leading to the development of higher-risk plaque types.

Researchers found plaque was more prevalent in people with rheumatoid arthritis, with a higher prevalence of plaque calcification also found.

They found higher levels of the biomarkers hs-CRP and IL6 can be linked to greater inflammation.

WHAT IS RHEUMATOID ARTHRITIS?

GETTY

Getty

1 of 12

Rheumatoid arthritis is an incredibly debilitating condition that affects more than 400,000 people within the UK.

Rheumatoid arthritis is an autoimmune condition, which means it is caused by the immune system attacking healthy body tissue - such as the lining go the joints.

It causes joints to become sore and inflamed and damages bones, cartilage, tendons and ligaments.

If the condition isn't treated, these chemicals gradually cause the joint to lose its shape and alignment.

Experts said the results could reveal that a combination of IL6 and hs-CRP represent a significant driver of cardiovascular risk.

GETTY

The researchers concluded: "This study confirms increased prevalence of atherosclerosis in rheumatoid arthritis and provides data to support the hypothesis that patients have a high-risk plaque phenotype."

Dr Natalie Carter, head of research liaison and evaluation at Arthritis Research UK, said: "Rheumatoid arthritis is an incredibly debilitating condition that affects more than 400,000 people within the UK.

The condition can not only limit a person's ability to live their everyday life to the full, but it can also put them at higher risk of cardiovascular disease.

"This study not only reinforces the link between rheumatoid arthritis and cardiovascular disease, but the results can also help us understand what causes atherosclerosis in both patients with rheumatoid arthritis and the general public."

Atherosclerosis occurs when fatty material called atheroma builds up in the lining of your artery walls and narrows your arteries.

Over time it can grow bigger until your arteries become so narrow that they cant let enough blood through.

Go here to see the original:
Rheumatoid arthritis could be linked to heart condition ... - Express.co.uk

UNC student dispels stereotype, seeks arthritis cure News & Observer Barber has had arthritis since she was 13. She is one of two Triangle residents chosen by the Triangle/Coastal Office of the Arthritis Foundation to be the face of arthritis and to help spread the word about the Triangle Walk to Cure Arthritis on ...

More here:
UNC student dispels stereotype, seeks arthritis cure - News & Observer

BISMARCK, N.D. Everyday activities can sometimes be taken for granted.

For years, a Bismarck woman couldn't perform actions as simple as turning a key because of rheumatoid arthritis.

For most of us, a task like opening the door doesn't require much thought.

But, for Julie Pfliiger, it's one of the many simple actions that gave her pain for years.

"At the time my husband had to get me out of bed. Tie my shoes. I was really incapacitated," said Pfliiger.

Pfliiger suffered from rheumatoid arthritis, a disorder that causes painful swelling in joint linings.

Opening jars, turning a faucet, and even driving challenged her.

"I really didn't go anywhere other than work. And work was really tough at the time," said Pfliiger.

Pfliiger had the condition for 12 years before she underwent surgery at Sanford Health.

During a series of four surgeries, her tendons were tightened and one of her wrists was fused.

Then she started working with a hand therapist to make the surgery effective.

"We went from supporting it, protecting it, to getting the motion, to strengthening within the course of several months," said Cory-Vatnsdal Gezk, hand and occupational therapist

Vatnsdal Gezk says Pfliiger's condition was one of the most extreme she's ever seen in patients, but her recovery was one of the most successful ones.

"To help her son get dressed, to turn a key in her car, to turn a doorknob, get dressed, do her laundry. Cook, cut food, the things that you and I take for granted she does wonderful now," said Vatnsdal Gezk.

Pfliiger continues to work with her therapist to gain strength in her hands and wrists.

See the rest here:
Sanford Health helps woman with rheumatoid arthritis - KFYR-TV

The survey found that because treatments don't always work as well as patients would like, people living with RA have tried an average of more than four prescription medications in the last 5 years.1

In addition, the survey revealed a need for more support of RA patients, particularly when it comes to the conversations they have with their physicians about treatments. Although a majority of respondents say that doctors are their go-to source for information on treatment options for RA (91 percent), many people living with RA (58 percent) delay seeing a doctor right away if their treatment stops working.1 Those surveyed cited several reasons for the delay, including because they think the symptoms will go away on their own (41 percent of those who delay) or they don't want to switch to a perceived stronger medication with potentially more side effects (37 percent of those who delay).1

"The Honestly RA results reveal there is a clear need for more support of RA patients from management of the disease impact on their life to the conversations that they have with their physicians," said Dr. Olga Petryna, Rheumatologist and Clinical Instructor at NYU Langone. "Many patients are dissatisfied with their current treatment and express frustration when a switch in treatment is needed. That's why physicians and the broader support community need to engage those patients who may be struggling to meet their treatment goals in an open conversation."

Notably, people with RA also feel a lack of empathy from others around them. Ninety percent of Honestly RA respondents said that given RA is a largely "invisible" disease, it is frustrating when others do not understand how much pain they are in.1

"My pain affects almost every area of my life work, travel, spending time with friends and family and it can be frustrating when someone doesn't understand the impact," said RA patient, blogger and advocate, Angela Lundberg. "I know it can be difficult, but I encourage everyone living with RA to not be afraid of speaking up, initiating a conversation with your doctor about treatment and celebrating all of your little achievements no matter how small they seem, or how hard they are for someone else to understand."

About the Survey Honestly RA included data from 1,004 patients aged 18 and up in the U.S. who self-reported they were diagnosed with RA and whose treatment journey had progressed beyond just a Non-Steroidal Anti-Inflammatory Drug (NSAID). The online survey was fielded between July 25 and August 8, 2016 by Edelman Intelligence on behalf of Sanofi and Regeneron.

About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

AboutRegeneron Pharmaceuticals, Inc. Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit http://www.regeneron.com or follow @Regeneron on Twitter.

Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

1 Honestly RA Survey Results PPT, Oct. 2016. 2 Mayo Clinic. "Rheumatoid Arthritis." Available at http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388. Last accessed March 2017.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/survey-results-show-eighty-percent-of-rheumatoid-arthritis-patients-report-life-altering-pain-daily-or-multiple-times-a-week-despite-treatment-300449267.html

SOURCE Regeneron Pharmaceuticals, Inc.

View post:
Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple ... - PR Newswire (press release)

The ability of stem cells to divide into different mature cell types has ignited the field of regenerative medicine. Stem cells promise to repair and regenerate damaged or diseased tissues without the need for orthodox medical or surgical interventions.

However, there is disparity between the expectations held by the general public and some medical professionals versus the reality of the emerging clinical evidence. This disconnect was highlighted recently by the case of three elderly patients who were blinded by the use of an unproven stem cell therapy at a clinic in Florida, USA (BioNews 893).

While stem cell therapies in the field of haematology are showing promise, there are still many challenges in using them in any other disease models. In some countries, medical professionals are using unproven stem cell therapies as medical procedures to treat patients in lieu of conventional treatment pathways. What is more, these practitioners are operating under the premise of a trial.

Proponents of using stem cell therapies outside the context of a true clinical trial believe that these therapies are inherently safe, particularly if the stem cells derive from the individual patient themselves. And the medical professionals offering unproven stem cell therapies are convinced that the potential benefits of undergoing the therapy far outweigh the potential risks.

These benefits are used as an argument to forge ahead with unproven therapies outside ofclinical trials, as regulatory bodies are often to slow to regulate for the fast-paced field of regenerative medicine;gaining regulatory approval is usually a lengthy and costly process. And the regulation that is in place is often narrow in scope and does not account for the variety of products and manipulative techniques used in the field.

An anecdotal account of a stem cell therapys potential to cure a disease, however, does not make for an adequate standard of evidence. In the Florida case, three elderly patients with a progressive eye disease sought out an unproven stem cell therapy. The clinic involved was offering the therapy under the guise of a trial, however the patients had to pay for the procedure (in itself a 'red flag') that promised to 'cure' their disease. The therapy not only failed, but all three patients are now blind as described in The New England Journal of Medicine on 16 March.

Referring back to the disparity in expectations, how the word 'trial' is understood helps to clarify the basis of thedisconnect between the public and clinicians, and emerging evidence. The word 'trial' in the sense of a clinical trial calls for a robust experimental framework and sets of regulations and standards that safeguard the enrolled patients' rights and overall health. Furthermore, trials are performed in a phased manner to ensure any potential risks are minimised. The results generated from a certain phase informs the researchers as to the most effective way to proceed or indeed not proceed.

Using the word 'trial' in the sense of administering a therapy outside of the setting described above, however, only truly refers to the inherent risk of the therapy not working. Moreover, when being administered by a trusted medical professional, the harms of the therapy are often overshadowed by the promise of a'cure' relayed bythese professionals.

The differences in the interpretation of the word trial among medical professionals is reflected by the lack of strict regulation among professional bodies, such as medical councils and regulatory bodies including the Food & Drug Administration (FDA). While the FDA, for example, has published more specific guidelines in October 2015, these are unenforceable on a global scale.

Interestingly, on a regulatory level, there are opportunities afforded to medical professionals to use unproven stem cell therapies outside the context of a clinical trial as noted in the International Society for Stem Cell Research (ISSCR) 2016 guidelines:

...the ISSCR acknowledges that in some very limited cases, clinicians may be justified in attempting medically innovative stem cell-based interventions in a small number of seriously ill patients.

However the ISSCR goes on to clarify that it 'condemns' the use of unproven stem cell therapies in any other setting where clinical need is not deemed serious.

In relation to classifying unproven stem cell therapies as a medical procedure, the 2014 United States of America v Regenerative Sciences, LLC et al case dealt with the use of mesenchymal stem cells taken from a sample of a patient's own bone marrow to treat their own orthopaedic disorders. In this case, the court was not convinced that manipulating stem cells outside the body and reintroducing them to the patient was a matter of standard 'medical procedure', as argued by the companyRegenerative Sciences LLC. Instead, the court upheld the FDAs right to regulate the manufacturing (or manipulating) of these stem cells: however cases where there is significantly less manipulation of stem cells are yet to be tested.

Issues remain regarding how best to regulate the use of stem cell therapies, particularly in the early phases of their development. There have been calls for strict regulation through bodies such as the FDA, but others argue that strict regulation will only curtail the benefits stem cell therapies can impart. On the other hand, regulations that are too lenient, it is argued, will only harm the patient seeking the therapy, as a solid evidence base will not yet have been compiled for the therapy.

The rest is here:
BioNews - Unproven stem cell therapies promise versus evidence - BioNews

Stem cells that are grown in the lab are known to acquire mutations, but whether these mutations are particularly numerous or risky remains unclear. Mutations acquired in stem cell culture, it is feared, would complicate efforts to deploy stem cells in regenerative medicine. At the least, lab-grown stem cells may need to be screened for deleterious mutations, with special attention devoted to vulnerable portions of the genome or flaws that could lead to dire consequences, such as cancer.

To characterize the mutations that may arise among stem cells in vitro, scientists have been introducing gene-sequencing tests. For example, in a recent study, scientists based at Harvard have determined that human pluripotent stem cells are prone to develop mutations in the TP53 gene, which ordinarily helps suppress cancer. The mutated versions of the TP53 found by the Harvard team, however, tend to drive cancer development.

Details of this work appeared April 26 in the journal Nature, in an article entitled, Human Pluripotent Stem Cells Recurrently Acquire and Expand Dominant Negative P53 Mutations. This article describes how the Harvard team sequenced the protein-coding genes of 140 human embryonic stem cell (hES) cell lines26 of which were developed for therapeutic purposes using Good Manufacturing Practices, a quality control standard set by regulatory agencies in multiple countries. The remaining 114 human pluripotent stem cell lines were listed on the NIH registry of human pluripotent stem cells. This gene-sequencing exercise was followed by computational work that allowed the scientists to identify mutations present in a subset of cells in each cell line.

[We] identified five unrelated hES cell lines that carried six mutations in the TP53 gene that encodes the tumour suppressor P53, wrote the articles authors. The TP53 mutations we observed are dominant negative and are the mutations most commonly seen in human cancers. We found that the TP53 mutant allelic fraction increased with passage number under standard culture conditions, suggesting that the P53 mutations confer selective advantage.

The scientists also mined published RNA sequencing data from 117 human pluripotent stem cell lines, and observed another nine TP53 mutations, all resulting in coding changes in the DNA-binding domain of P53. In three lines, the authors of the Nature paper detailed, the allelic fraction exceeded 50%, suggesting additional selective advantage resulting from the loss of heterozygosity at the TP53 locus.

These findings suggest that cell lines should be screened for mutations at various stages of development as well as immediately before transplantation.

"Our results underscore the need for the field of regenerative medicine to proceed with care," said the study's co-corresponding author Kevin Eggan, Ph.D. "[They] indicate that an additional series of quality control checks should be implemented during the production of stem cells and their downstream use in developing therapies. Fortunately, these genetic checks can be readily performed with precise, sensitive, and increasingly inexpensive sequencing methods."

"Cells in the lab, like cells in the body, acquire mutations all the time," added Steve McCarroll, Ph.D., co-corresponding author. "Mutations in most genes have little impact on the larger tissue or cell line. But cells with a pro-growth mutation can outcompete other cells, become very numerous, and 'take over' a tissue. We found that this process of clonal selectionthe basis of cancer formation in the bodyis also routinely happening in laboratories."

Although the Harvard scientists expected to find some mutations in stem cell lines, they were surprised to find that about 5% of the stem cell lines they analyzed had acquired mutations the TP53 gene, which encodes the tumor suppressor protein P53.

Nicknamed the "guardian of the genome," P53 controls cell growth and cell death. People who inherit p53 mutations develop a rare disorder called Li-Fraumeni Syndrome, which confers a near 100% risk of developing cancer in a wide range of tissue types.

The specific mutations that the researchers observed are "dominant negative" mutations, meaning, when present on even one copy of P53, they are able to compromise the function of the normal protein, whose components are made from both gene copies. The exact same dominant negative mutations are among the most commonly observed mutations in human cancers.

The researchers performed a sophisticated set of DNA analyses to rule out the possibility that these mutations had been inherited rather than acquired as the cells grew in the lab. In subsequent experiments, the Harvard scientists found that P53 mutant cells outperformed and outcompeted nonmutant cells in the lab dish. In other words, a culture with a million healthy cells and one P53 mutant cell, said Dr. Eggan, could quickly become a culture of only mutant cells.

"The spectrum of tissues at risk for transformation when harboring a P53 mutation include many of those that we would like to target for repair with regenerative medicine using human pluripotent stem cells," noted Dr. Eggan. Those organs include the pancreas, brain, blood, bone, skin, liver, and lungs.

However, Drs. Eggan and McCarroll emphasized that now that this phenomenon has been found, inexpensive gene-sequencing tests will allow researchers to identify and remove from the production line cell cultures with concerning mutations that might prove dangerous after transplantation.

The researchers point out in their paper that screening approaches to identify these P53 mutations and others that confer cancer risk already exist and are used in cancer diagnostics. In fact, in an ongoing clinical trial that is transplanting cells derived from induced pluripotent stem cells, or iPSCs, gene sequencing is used to ensure the transplanted cell products are free of dangerous mutations.

More here:
Stem Cells in Culture Have Tendency to Develop Cancer-Linked Mutations - Genetic Engineering & Biotechnology News

May 1, 2017 Ovarian cancer tumors with higher percentages of cIAP-expressing cells, shown in red at left, were more sensitive to a potential combination therapy than tumor cells without cIAP-expressing cells. Credit: UCLA Broad Stem Cell Research Center

Researchers have been trying to understand why up to 85 percent of women experience recurrence of high-grade serous ovarian cancerthe most common subtype of ovarian cancerafter standard treatment with the chemotherapy drug carboplatin.

Preclinical research from Dr. Sanaz Memarzadeh, who is a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, has potentially solved this mystery and pinpointed a combination therapy that may be effective for up to 50 percent of women with ovarian cancer.

Memarzadeh's research, published in the journal Precision Oncology, shows a new combination therapy of carboplatin and an experimental drug called birinapant can improve survival in mice with ovarian cancer tumors. Additional findings reveal that testing for a specific protein could identify ovarian tumors for which the treatment could be effective. Importantly, the treatment could also target cancers that affect other parts of the body, including the bladder, cervix, colon and lung cancer.

In 2015, Memarzadeh and her team uncovered and isolated carboplatin-resistant ovarian cancer stem cells. These cells have high levels of proteins called cIAPs, which prevent cell death after chemotherapy. Since the cancer stem cells survive carboplatin treatment, they regenerate the tumor; with each recurrence of ovarian cancer, treatment options become more limited. Memarzadeh showed that birinapant, which degrades cIAPs, can make carboplatin more effective against some ovarian cancer tumors.

"I've been treating women with ovarian cancer for about two decades and have seen firsthand that ovarian cancer treatment options are not always as effective as they should be," said Memarzadeh, director of the G.O. Discovery Lab and member of the UCLA Jonsson Comprehensive Cancer Center. "Our previous research was promising, but we still had questions about what percentage of tumors could be targeted with the birinapant and carboplatin combination therapy, and whether this combination could improve overall survival by eradicating chemotherapy-resistant ovarian cancer tumors."

In this new study, the research team first tested whether the combination therapy could improve survival in mice. Half of the mice tested had carboplatin-resistant human ovarian cancer tumors and the other half had carboplatin-sensitive tumors. The team administered birinapant or carboplatin as well as the two drugs combined and then monitored the mice over time. While birinapant or carboplatin alone had minimal effect, the combination therapy doubled overall survival in half of the mice regardless of whether they had carboplatin-resistant or carboplatin-sensitive tumors.

"Our results suggest that the treatment is applicable in some, but not all, tumors," said Rachel Fujikawa, a fourth year undergraduate student in Memarzadeh's lab and co-first author of the study.

To assess the combination therapy's rate of effectiveness in tumors, the team went on to test 23 high-grade serous ovarian cancer tumors from independent patients. Some were from patients who had never been treated with carboplatin and some were from patients who had carboplatin-resistant cancer.

With these samples, the researchers generated ovarian cancer tumors utilizing a method called disease-in-a-dish modeling and tested the same treatments previously tested in mice. Once again, carboplatin or birinapant alone had some effect, while the combination of birinapant and carboplatin successfully eliminated the ovarian cancer tumors in approximately 50 percent of samples. Importantly, the combination therapy worked for both carboplatin-resistant and carboplatin-sensitive tumors.

The researchers also measured cIAPs (the target for the drug birinapant) in the tumors. They found a strong correlation between cancer stem cells with high levels of cIAP and a positive response to the combination therapy. Since elevated levels of cIAPs have been linked to chemotherapy resistance in other cancers, the researchers wondered if the combination therapy could effectively target those cancers as well.

The team created disease-in-a-dish models using human bladder, cervix, colon and lung cancer cells and tested the combination therapy. Similar to the ovarian cancer findings, 50 percent of the tumors were effectively targeted and high cIAP levels correlated with a positive response to the combination therapy.

"I believe that our research potentially points to a new treatment option. In the near future, I hope to initiate a phase 1/2 clinical trial for women with ovarian cancer tumors predicted to benefit from this combination therapy," said Memarzadeh, gynecologic oncology surgeon and professor at the David Geffen School of Medicine at UCLA.

Explore further: Combination therapy may be more effective against the most common ovarian cancer

More information: V. La et al, Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy, npj Precision Oncology (2017). DOI: 10.1038/s41698-017-0008-z

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.

About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment, report scientists from Dana-Farber ...

Adding an aromatase inhibitor to presurgery treatment with docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (Perjeta) did not significantly increase or decrease the percentage of patients with hormone receptor ...

Treating ovarian cancer with platinum-based chemotherapy drugs such as cisplatin is initially very effective, with about four out of five patients responding favorably. However, most of these patients quickly become resistant ...

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main ...

Using the gene-editing system known as CRISPR, MIT researchers have shown in mice that they can generate colon tumors that very closely resemble human tumors. This advance should help scientists learn more about how the disease ...

Researchers have been trying to understand why up to 85 percent of women experience recurrence of high-grade serous ovarian cancerthe most common subtype of ovarian cancerafter standard treatment with the chemotherapy ...

Immunotherapy, in which cells from the human immune system are unleashed to fight disease, has been the big story in cancer treatment over the past few years. When it works, it can spur long-lasting remission in patients ...

A collaborative Cleveland Clinic, University of Oxford and Moffitt Cancer Center team of researchers has proven the theory that, while resistance to targeted treatment in cancer is truly a moving target, there are opportunities ...

Scientists have described new results of a blood cancer study as 'outstanding' in tackling previously untreatable forms of chronic lymphocytic leukaemia (CLL).

Researchers from the transformation and metastasis group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Eva Gonzlez-Surez, have recreated and characterized the development of resistance to chemotherapy ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Combination therapy could provide new treatment option for ovarian cancer - Medical Xpress

It was a normal day for John Sabec on June 16, 2011, when he fell asleep at his home in Pueblo, Colorado.

But his life was anything but normal when he awoke the next morning.

And it hasnt been ever since.

That night almost six years ago he lost his vision from diabetic retinopathy. He woke up with no vision in his left eye and large gray spots blocking his vision in his right eye.

The retina in my left eye exploded, he said. A surgeon was able to reattach the retina in his right eye, but he has very limited vision, which he compares to looking through a toilet paper roll.

Sabec sank into a depression and withdrew from life for several years. But hes managed to turn his life around.

Hes now attending Helena College working on an associate degree and is a work study employee for the colleges Disability Resource Office.

What happened to him gives him a unique view into the challenges students with disabilities face.

I work with anybody with a recognized disability, he said, whether it be physical, learning or emotional. More than 100 students are registered with the Helena College office and have a documented disability.

I can empathize with a lot of people, Sabec said. I know what its like to have something taken away from you. Ive been in the same boat.

Sabec's service dog Benjamin lays at his feet recently.

As far as assistance for his own disability, the college puts his books on PDFs that he can enlarge on his home computer till the lettering is big enough for him to read. Or the computer can turn it into an audio recording he can listen to.

Accompanying him in his work and studies is his service dog, a black lab named Benjamin.

John schedules appointments, proctors tests and creates and maintains student files, said Kristine Fife, the Helena College disability resource coordinator.

The office provides a wide range of accommodations for students with disabilities ranging from physical to cognitive to psychiatric.

Anyone with documented needs can receive resources, Fife said.

John has overcome a lot with different health issues, she said. Hes shown an incredible amount of perseverance despite barriers, she said.

His own disability heightens his ability to be empathetic and assist students with disabilities.

At the time he lost his vision, I went into depression and thought my life was over, he said. I isolated myself. I wasted 2 1/2 to 3 years of my life.

I worked in law enforcement most of my adult life and was driving a paratransit bus.

He jokes that he went from driving the short bus to riding it.

June 16, 2011, was the last day he ever drove -- although it took him years, he admits, to give up the idea of being a licensed driver. Driving was a big deal to me.

Sabec wound up moving to Hardin in 2012 to be near his children, and through their help he learned of the National Federation of the Blind.

Once he began working with that organization, he discovered life doesnt end if you lose your eyesight.

In 2014 he found his way to Helena and now feels right at home.

I just like the Helena area, he said. It has big city amenities with a small town feel.

He started at Helena College in fall of 2015 and plans on graduating in fall 2017, and he wants to go on to earn a four-year degree at a Montana campus to become a disabilities advocate.

Hes been earning a 3.7 grade point average and is on the deans list.

This office has been amazing, he said. Kris has been amazing. Shes one of my reasons for success.

Everyone here is professional and caring, he said. Ive had a teacher who has gone above and beyond a teacher and is a real good friend.

Its awesome -- like a family. Everyone wants to see everyone succeed here. I just think if youre looking to further your education or become a success in life, Helena College is a great place to start.

Its given me confidence to be productive in life and to socialize again.

What hes learned from life, Sabec said, is he needs to keep striving to move forward. Whats difficult today is a speed bump. Theres smooth sailing for a while and then another speed bump.

Continue reading here:
Sudden blindness opened Helena man's eyes to a new life - Helena Independent Record

May 01, 2017 07:30 ET | Source: Research and Markets

Dublin, May 01, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/6hlgn5/animal

Source: Jain PharmaBiotech

About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Continued here:
Animal Biotechnology Technologies, Markets and Companies 2016-2026 - GlobeNewswire (press release)

TORONTO, May 1, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, California.

"We are pleased to be a contributor to this very prestigious conference," said Andrew Morris, CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believeour unique productswill prove to be beneficial to our customers who are large, global pharmaceutical companies.

The conference will run from May 1-3, 2017. Please stop by and visit us at booth 316.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit http://www.sqidiagnostics.com.

Contacts:

Sales and Marketing Contact: Russ Peloquin Vice President, Global Commercial Operations 913.484.9022 rpeloquin@sqidiagnostics.com

Investor Relations Contact: Andrew Morris Chief Executive Officer 416.674.9500 ext. 229 amorris@sqidiagnostics.com

Forward-looking Information

This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "may", "expects", "intends", "anticipates" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. The forward-looking statements in this news release include without limitation, statements with respect to the Private Placement and the use of proceeds of the Private Placement. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory and stock exchange approvals, general economic and market segment conditions, and international risk and currency exchange risks, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at http://www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Read More

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The rest is here:
SQI Diagnostics to Exhibit at the National Biotechnology Conference - Yahoo Finance

[Editors note: Tess Doezema is a doctoral student at the School for the Future of Innovation in Society at Arizona State University, where she researches biotechnology promise and politics.]

[S]cientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.

Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance.

Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.

Originally posted here:
Are you 'anti-science' if you resist biotechnology on political or economic grounds? - Genetic Literacy Project

The Newburgh Press

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... StockNewsUnion Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) continues to power high in the market on the back of a recently announced product distribution deal. A deal with Xenetic Biosciences is expected to make the company's products available on the ... Traders are Following Technical Levels for Prana Biotechnology Ltd (PRAN)Rives Journal Does Prana Biotechnology Limited (PRAN)'s current closing price competes the market?TopChronicle Notable Institutional Stake In These Stocks: Prana Biotechnology (NASDAQ:PRAN), Adamis Pharmaceuticals ...Wallstreet Investorplace TRA -The Newburgh Press -Is stories all 13 news articles »

See the original post here:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... - StockNewsUnion

USA Commerce Daily

379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... The Cerbat Gem Emerald Advisers Inc. PA bought a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent Form 13F ... Should You Buy, Sell, Or Hold? - Puma Biotechnology, Inc. (PBYI), SkyWest, Inc. (SKYW)USA Commerce Daily Emerald Mutual Fund Advisers Trust Takes Position in Puma ...BBNS Puma Biotechnology (PBYI) Getting Somewhat Negative Press ...Chaffey Breeze HugoPress -Rives Journal -W News all 17 news articles »

More:
379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... - The Cerbat Gem

A 4,000 year-old medical tradition from India is the inspiration for a local researcher whos looking for new ways to treat and prevent arthritis.

In the lab hes unlocking the healing properties of herbs, fruits, and flowers.

In this weeks Exploradio, WKSUs Jeff St.Clair explores how modern science is revealing the ancient secrets of Ayurveda.

My mother suffered from arthritis," says Northeast Ohio Medical University researcherTariqHaqqi.

He says aspirin and other conventional treatments didnt help, so she sought a traditional healer who prescribed certain herbs.

And my mother felt quite a bit of pain relief and she was even able to walk after those medicines, so those things were in my mind from my childhood.

Inspired by that success, Haqqi now studies how natural remedies work to relieve arthritis.

We are studying the pomegranate extract. We are studying also another medicinal plant from India called Butea monosperma, and we are studying a purified compound called woginin, which is from the Chinese traditional medicine system.

Pomegranate fruit and juice is everywhere. Butea monosperma, or the Flame of the Forest tree, and the compound woginin from the Chinese skullcap flower (Scutellaria baicalensis) are a little less familiar.

Haqqi is testing all of them as potential arthritis medicines.

Healing properties of pomegranates

In a recent study Haqqi fed rabbits with surgically induced arthritis a pomegranate extract both before and after the surgery.

He found that the cartilage in the knees of rabbits that ate pomegranates was relatively untouched by arthritis.

We are not seeing the cartilage degradation here," says Haqqi, "because the enzymes which are involved in matrix breakdown are not being allowed to go up.

Haqqi says compounds in the pomegranates migrate to the synovial fluid surrounding the knee joints, seep into the cells, and block the breakdown of the tissue.

One of his students is testing an extract of flowers from the Flame of the Forest tree to see if it has a similar effect in humans.

Flame of the Forest flowers

Mohammad Ansari shows me a petri dish with a thin layer of liquid that he says contains five million cells, which under a microscope look like misshapen polygons.

Theyre called chondrocytes.

All the cartilage in your body, your knees, your nose, your ears, all of it comes from this one type of cell.

In the petri dish Ansari treats the chondrocytes with an inflammatory protein called Interleukin 1 betathat triggers the breakdown of cartilage basically inducing arthritis - then he adds the Flame of the Forest flower extract.

Ansari says compounds from the flower extract called polyphenols stop the cartilage breakdown.

They inhibit these pathways," that cause inflammation, Ansarisays, and boost the growth of the cartilage matrix.

Ayurveda's ancient knowledge

The fact that these plants have healing properties is no surprise to Marc Halpern, founder of the California College of Ayurveda.

Theres no shortage of evidence supporting the effectiveness of Ayurvedic medicine today.

Ayurveda translates as the "science of life."

Its a system of medicine that originated in India around 4,000 years ago, preserved in ancient texts.

The textbooks of Ayurvedic medicine describe almost every condition that we face todayfrom cancer to ulcerative colitis, to pneumonia, to interstitial cystitis, kidney stones

The texts include descriptions of herbs like the ones Tariq Haqqi is testing in his lab.

How does the Ayurvedic system of medicine work?

Ayurveda is a science of understanding what is right for you, says Halpern.

Were all different, says Halpern, and so is the way we respond to remedies.

The closest thing to it in Western thought would be our genetic makeup. We each have unique biochemical needs. Ayurveda has understood this for thousands of years.

Halpern looks at 50 or so physical characteristics, your pulse, skin, eyes, digestion to determine what he calls your Ayurvedic constitution and tendencies.

The emphasis, he says, is on prevention, and once we understand their tendencies, then we can work with those tendencies to define a diet and lifestyle thats right for that person.

Halperns college is the only school in the country that certifies Ayurvedic doctors, the highest level of accreditation.

Currently there are only a handful of Ayurvedic doctors in America. But the number of Ayurvedic practioners and health counselors is growing.

Halpern looks forward to the day when Ayurveda goes mainstream.

Eventually the day will come where you see an advertisement for Ayurvedic medicine during the superbowl!

He is working with a yoga studio in Columbus to train Ayurvedic practioners.

Meanwhile at NEOMED, Tariq Haqqi is for seeking new, safer treatments for arthritis, using Ayurveda as inspiration.

It is now for us to go deeper into it with modern science.

See the article here:
The Ancient Science of Ayurveda Inspires Arthritis Research At ... - WOSU

Durham Herald Sun

UNC student dispels stereotype, seeks arthritis cure Durham Herald Sun Barber has had arthritis since she was 13. She is one of two Triangle residents chosen by the Triangle/Coastal Office of the Arthritis Foundation to be the face of arthritis and to help spread the word about the Triangle Walk to Cure Arthritis on ...

Go here to see the original:
UNC student dispels stereotype, seeks arthritis cure - Durham Herald Sun

GETTY

Many children lose their sight or suffer impaired vision due to an inflammatory complication of the condition.

Scientists believe they may have uncovered the silver bullet when it comes to stopping this devastating damage.

A pioneering trial, funded by the charity Arthritis Research UK and the National Institute for Health Research (NIHR), has discovered a drug combination which has very impressive results.

The trial was first of its kind in the world and the findings are being hailed as a major step forward for thousands of children.

The trial's co-chief investigators, Professors Athimalaipet Ramanan, based at Bristol's Children Hospital and Michael Beresford, based in Liverpool, found that a drug called Adalimumab, in combination with Methotrexate, was an effective therapy in children with arthritis who go on to develop Uveitis an inflammation of the eye A staggering 75 per cent of those treated with the medication experienced a significant reduction in eye inflammation.

Early analysis of the data was so convincing that the trial was stopped prematurely.

GETTY

Professor Ramanan, who also works at Bristol University, said, Uveitis in children is an important cause of loss of vision.

This study demonstrates the benefit of Adalimumab in children with uveitis. This is the first randomised trial of its kind worldwide and the results will have a major impact in children with uveitis all around the world.

Professor Beresford from University of Liverpool and Alder Hey Children's NHS Foundation Trust said: This landmark trial has demonstrated the commitment and leadership of colleagues across the UK in working closely with patients and parents in tackling a key priority of finding the very best way of caring for children with arthritis and this serious problem of uveitis.

It has shown the UK to be extremely well placed to deliver challenging trials in children, with the support of the NIHR Clinical Research Network and other research networks that are in place across the UK.

There are 15,000 children and adolescents in the UK with the auto-immune disease JIA. One third of those are likely to develop uveitis, leading to more serious visual impairments and may be registered as blind.

1 of 11

GETTY

Stephen Simpson, the director of research and programmes at Arthritis Research UK said: We are thrilled of the outcome of this trial and the huge promise it heralds for transforming the quality of life for the large numbers of children with JIA-associated uveitis.

This trial is an impressive example of how investing in exceptional science can ultimately help change how treatment is delivered with direct and immediate benefit for patients.

Go here to read the rest:
British trial will save the sight of thousands of arthritic children - Express.co.uk